Amgen sues FDA to get paediatric exclusivity for Sensipar

Amgen has filed a complaint against the US Food and Drug Administration (FDA) for not accepting its study reports and denying six months of paediatric exclusivity for its drug Sensipar (cinacalcet).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

BMS signs $15.2bn deal with China’s top pharma company

14 May 2026 The agreement is the latest in a string of major deals between Hengrui and multinational drugmakers, and will see the parties jointly develop assets while licensing others.

Americas

Medtech company sues over seven patents for incontinence products

13 May 2026 PureWick claims that two rivals infringed its external catheter and urine-management technology in their medical devices.

Americas

10x Genomics settles suit with rival and targets DNA sequencing startup

12 May 2026 The dominant player in the spatial biology market has sued a San Diego-based life sciences company over its genetic analysis technology, as another lawsuit in its patent litigation campaign approaches conclusion.

More features

Blank Rome adds to growing team with patent agent from MBHB

BMS signs $15.2bn deal with China’s top pharma company

Medtech company sues over seven patents for incontinence products

10x Genomics settles suit with rival and targets DNA sequencing startup

Trade secrets, AI and the new scrutiny of big damages awards

WATCH: Interview with Mythili Markowski, director at Regeneron

IP in the deal room: The risks that bite before, during and after closing

Teva can pursue monopoly claims over rival’s ‘exclusive pharmacy deal’

Amgen sues FDA to get paediatric exclusivity for Sensipar

More on this story

Editor's picks

Editor's picks

More features